Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News


thepharmaletter.com > pharma-news > positive-results-for-novo-nordisk-step-young-phase-iii-trial-in-children

Positive results for Novo Nordisk STEP Young Phase III trial in children

1+ week, 6+ hour ago   (239+ words) The Pharma Letter - Positive results for Novo Nordisk STEP Young Phase III trial in children Danish pharma major Novo Nordisk (NOV: N) today announced first results from the STEP Young Phase III trial, evaluating once-weekly semaglutide in combination with a reduced-calorie…...


thepharmaletter.com > biotech-news > novartis-btk-inhibitor-clears-phase-iii-hurdle-in-relapsing-ms

Novartis BTK inhibitor clears Phase III hurdle in relapsing MS

1+ week, 5+ day ago   (212+ words) The Pharma Letter - Novartis BTK inhibitor clears Phase III hurdle in relapsing MS Swiss pharma major Novartis (NOVN: VX) has reported that its oral candidate remibrutinib significantly cut relapse rates against French drugmaker Sanofi's (Euronext: SAN) Aubagio (teriflunomide) in two Phase…...